"It's appalling the way AstraZeneca has been treated. I wouldn't blame them if they were thoroughly fed up and decided to bow out of the Covid vaccine business." That was the view from one of the ...

LONDON, Nov 6 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not know the reason ...

The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

Steven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

In a notice issued to the London Stock Exchange on the company’s share price movement, AstraZeneca (AZN) stated: “As a matter of policy, we do not comment on speculative media reports ...

AstraZeneca disclosed Wednesday that Leon Wang, a high-ranking executive who oversees international operations and is also president of its subsidiary in China, is under investigation by Chinese ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00. Etzer Darout has given his Buy rating due to a ...